Please login to read the full article.
Scrip Regulatory Affairs
US FDA consults on fulfilling obligations for device post-market surveillance studies
17 August 2011
Vibha Sharma
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Calls for delay of EU medtech labelling decision as concerns continue
- EU industry cautious about proposed penalties under pharmacovigilance and paediatric frameworks
- US guidance explains which TV drug ads will be subject to FDA's 45-day pre-review rule
- US lawmakers ask regulators to address underreporting of clinical trial data
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
